Tag: SCS therapy

Boston Scientific announces positive WaveWriter SCS findings from SOLIS trial

Boston Scientific Corporation has announced positive one-year results from the SOLIS randomised controlled trial, demonstrating sustained pain relief using its WaveWriter Alpha spinal cord...

Saluda announces plans to present new EVOKE study data at NANS...

Saluda Medical has announced that its data will be presented at the upcoming North American Neuromodulation Society (NANS) annual meeting (18–21 January, Las Vegas,...

Washington state “poised” to extend spinal cord stimulation coverage following straw...

As per a recent statement from the North American Neuromodulation Society (NANS), the US state of Washington may be about to extend its insurance...

Nevro announces “profound improvements” in non-surgical refractory back pain patients treated...

Nevro Corporation has announced the publication of new 24-month data from the SENZA-NSRBP multicentre randomised controlled trial (RCT) in the Journal of Neurosurgery: Spine. The...

Boston receives expanded US FDA approval of SCS therapy for painful...

Boston Scientific has announced that the US Food and Drug Administration (FDA) has approved an expanded indication of the WaveWriter Alpha spinal cord stimulator...

Biotronik announces new data supporting effectiveness of RESONANCE multiphase stimulation paradigm

Biotronik Neuro has announced that results from the BENEFIT-02 trial—the “first of its kind” to clinically evaluate a multiphase stimulation paradigm—support the effectiveness of...

Medtronic receives CE-mark approval for Inceptiv closed-loop SCS to treat chronic...

Medtronic has received CE-mark approval for its Inceptiv closed-loop rechargeable spinal cord stimulator in the treatment of chronic pain. Inceptiv is the first Medtronic spinal...

Health economic data show cost-dominance of Saluda’s EVOKE system over open-loop...

Saluda Medical has announced the publication of new health economic data in the Clinical Journal of Pain that provides “the strongest ever economic case” for the...

Cochrane Library urged to retract and revise recent SCS review over...

Pain physicians have urged the Cochrane Library to retract and revise a recent review of spinal cord stimulation (SCS) in the treatment of low...

Brain-computer interface plus SCS therapy enables thought-controlled walking after spinal cord...

Onward Medical has announced a recent publication in Nature showing that a wireless brain-computer interface (BCI) can use patients’ thoughts to modulate ARC therapy....

Abbott gains US FDA nod to treat non-surgical back pain with...

Abbott has announced that the US Food and Drug Administration (FDA) has approved its spinal cord stimulation (SCS) devices for the treatment of chronic...

The new standard for SCS therapy—neural activation measurement, targeting and maintenance

Jason Pope (Santa Rosa, USA) discusses closed-loop spinal cord stimulation (SCS) and its potential to provide sustained, holistic outcomes for chronic pain patients. In...

Review concludes SCS benefits do not outweigh associated risks and costs...

A recently published Cochrane review has concluded that the clinical benefits of spinal cord stimulation (SCS) do not outweigh the risks and costs associated...

High-frequency spinal cord stimulation may be associated with “significant decrease” in...

High-frequency spinal cord stimulation (HF-SCS) for treating chronic refractory low back pain (CRLBP) may be associated with a significant decrease in total healthcare costs,...

Spinal cord stimulation found to “instantly improve” post-stroke arm and hand...

Spinal cord stimulation (SCS) therapy has been shown to trigger instant improvements in arm and hand mobility, enabling people affected by moderate-to-severe stroke to...

Saluda Medical announces presentation of 36-month EVOKE trial data at NANS...

Saluda Medical has announced that late-breaking data from the "landmark" EVOKE clinical trial was presented at the recent North American Neuromodulation Society (NANS) annual...

Onward reports positive study results in restoring arm and hand function...

Onward Medical recently announced that the Up-LIFT pivotal study evaluating its non-invasive spinal cord stimulation (SCS) ARC-EX therapy achieved its primary effectiveness endpoint of...